Featured Story

  • Lohmann deal adds growth to Elanco sales in quick order

    Eli Lilly's animal health business, Elanco, provides a bit of a bright spot in an otherwise weak earning report for its second quarter, with sales globally up more than 10%, while revenues across the entire company were up just 1%.

USDA, Nebraska U. researchers find no danger in Merck's Zilmax

A study carried out the University of Nebraska, Lincoln and the U.S.D.AU Agricultural Research Service found Zilmax had no negative effects on cattle health.

Eco's poultry and swine antibiotic Aivlosin key to revenue growth

Eco Animal Health Group said its profit has grown 8% to $24 million in the year ending March 31, and it owes much of that growth to its star product, Aivlosin, an antibiotic for poultry and swine targeting respiratory and enteric diseases.

In Purina v. Blue Buffalo, how far will manufacturers go?

A Bloomberg editor takes to the halls of dog food producer Blue Buffalo in Wilton, CT, to find out if the company is "built on lies," as alleged by the company's archnemesis, Purina.

North American sales propel growth at Abaxis

Medical products company Abaxis reported its end-of-quarter earnings, boasting 10% more revenue than the same period last year--growth which the company has attributed to its animal health unit.

Court stands with FDA on its approach to antibiotics use in farm animals

Scientific evidence proves a correlation between nonmedical use of antibiotics to fatten farm animals and spikes in antibiotic-resistant infections. So why was a federal appeals court panel divided over whether these drugs can be added to animal feed even if the drugs aren't medically necessary? The short, simple answer is that the FDA has just been giving advice on the practice.


From Our Sister Sites


After Sarepta Therapeutics' former head scientist blamed his swift ouster on "serious disagreements" with CEO Chris Garabedian, the company has moved to limit its chief executive's power, according to a report, especially when it comes to meetings with the FDA over the biotech's much-scrutinized lead drug.


Bracing for an expensive round of late-stage studies and potential drug launches as it ramps up work on a slate of new biosimilars, Amgen reported Tuesday evening that it plans to trim up to 15% of the company's workforce, shutting down facilities in Colorado and Washington state as it slashes up to 2,900 staffers.